LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1 | 0.0% | 1,330 | -3.8% | 0.00% | – |
| Q2 2023 | $1 | -100.0% | 1,383 | -66.6% | 0.00% | – |
| Q1 2022 | $6,000 | -57.1% | 4,135 | -31.8% | 0.00% | – |
| Q4 2021 | $14,000 | -90.4% | 6,063 | -88.2% | 0.00% | – |
| Q3 2021 | $146,000 | 0.0% | 51,383 | 0.0% | 0.00% | – |
| Q2 2021 | $146,000 | -13.1% | 51,383 | -28.2% | 0.00% | – |
| Q1 2021 | $168,000 | +1300.0% | 71,610 | +450.3% | 0.00% | – |
| Q3 2020 | $12,000 | +9.1% | 13,014 | -2.3% | 0.00% | – |
| Q2 2020 | $11,000 | – | 13,314 | +15563.5% | 0.00% | – |
| Q4 2019 | $0 | – | 85 | +16.4% | 0.00% | – |
| Q3 2019 | $0 | – | 73 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $85,694,000 | 4.37% |
| Defender Capital, LLC. | 4,798,270 | $12,707,000 | 4.13% |
| Raffles Associates | 93,590 | $236,000 | 0.22% |
| Prescott General Partners LLC | 1,851,851 | $4,667,000 | 0.16% |
| DCF Advisers, LLC | 87,000 | $219,000 | 0.10% |
| Laidlaw Wealth Management LLC | 104,841 | $264,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $113,000 | 0.06% |
| Strategic Wealth Investment Group, LLC | 70,625 | $179,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $121,000 | 0.04% |
| Sightline Wealth Advisors, LLC | 14,958 | $38,000 | 0.03% |